RESEARCH TRIANGLE PARK, N.C., Sept. 21, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced the closing of an underwritten public offering of 3,450,000 shares of its common stock at a public offering price of $60.00 per share, including 450,000 shares sold pursuant to the full exercise of the underwriters’ option to purchase additional shares. G1 Therapeutics received approximately $195.1 million in proceeds from the offering, net of underwriting discounts and commissions, but before estimated offering expenses.

J.P. Morgan Securities LLC and Cowen and Company, LLC served as joint book-running managers for the offering. Needham & Company, LLC and Wedbush Securities Inc. acted as lead managers for the offering. BTIG, LLC and H.C. Wainwright & Co., LLC acted as co-managers for the offering.

About G1 Therapeutics

G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of innovative therapies that improve the lives of those affected by cancer. The company is advancing three clinical-stage programs, trilaciclib, lerociclib and G1T48, that are designed to enable more effective combination treatment strategies and improve patient outcomes across multiple oncology indications.

G1 is based in Research Triangle Park, NC.